.png){kind=icon}
.png){kind=icon}
Return
Clinical trials in graft-versus-host disease: changes in study characteristics, investigated drugs, and endpoints over time
.png){kind=icon}
OA
AI
P
N
L
J
H
A
M
H
W
DOI：10.1016/j.jtct.2026.06.023.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Response is the key primary endpoint in graft-versus-host disease trials (60.1%). • There has been a shift toward biology-based treatments and specific drug targets. • Industry-sponsored trials have risen over the last two decades (13.4% to 38.9%). • Multinational and multi-center collaborations have increased in recent years.
Keywords:
GvHD
trial design
treatments
statistics
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4.4
Papers:
2.1K
Citations:
4.4K
Organization
Cited Papers